

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Australian Clinical Labs Limited (ACL)
ABN	94 645 711 128

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Melinda McGrath
Date of last notice	27 September 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	A.C.N. 633 176 100 Pty Ltd (ACN 633 176 100) as trustee for the McGrath Family Trust is the registered holder of ordinary shares in ACL. Melinda McGrath is a director of A.C.N. 633 176 100 Pty Ltd and is a beneficiary of the McGrath Family Trust.
Date of change	13 March 2023
No. of securities held prior to change	2,923,331 ordinary shares, comprising of 2,173,867 ordinary shares held directly and 749,464 ordinary shares held indirectly. 247,252 Performance rights (Rights) issued in accordance with the ACL long-term variable remuneration plan (LTVR Plan) in respect of the financial year ending 30 June 2022. The Rights will only vest in accordance with the provisions of the LTVR Plan.
Class	Rights issued in accordance with the LTVR Plan as approved by shareholders at ACL's 2022 AGM
Number acquired	238,092

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	The Rights have a nil exercise price but are calculated by reference to a Black-Scholes model valuation of \$3.78 per Right.
No. of securities held after change	2,923,331 ordinary shares, comprising of 2,173,867 ordinary shares held directly and 749,464 ordinary shares held indirectly. 485,344 Rights issued in accordance with the ACL LTVR Plan in respect of the financial years ending 30 June 2022 and 30 June 2023. The Rights will only vest in accordance with the provisions of the LTVR Plan.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Rights issued in accordance with the ACL LTVR Plan as approved by shareholders at ACL's 2022 AGM.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

⁺ See chapter 19 for defined terms.

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.